Merck & Co Inc

NYSE:MRK  
93.51
+1.42 (+1.54%)
4:37:35 PM EDT: $93.64 +0.13 (+0.14%)
Products, Regulatory

Merck Receives Positive EU CHMP Opinion For Keytruda

Published: 03/25/2022 13:20 GMT
Merck & Co Inc (MRK) - Merck Receives Positive Eu Chmp Opinion for Keytruda® (pembrolizumab) Plus Chemotherapy, With Or Without Bevacizumab, As Treatment for Patients With Persistent, Recurrent Or Metastatic Cervical Cancer Whose Tumors Express Pd-l1 (cps ≥1).
Merck & Co Inc - Opinion Granted Based on Positive Results From Phase 3 Keynote-826 Trial.
Merck & Co - Chmp's Recommendation to Now Be Reviewed by Eu for Marketing Authorization in European Union, Final Decision is Expected in Q2 of 2022.